Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines

Anti-Cancer Drugs

Volumn 23, Issue 10, 2012, Pages 1032-1038

  Virag, Piroska ^a   Perde Schrepler, Maria ^a   Fischer Fodor, Eva ^a   Tatomir, Corina ^a   Dorneanu, Sorin A ^b   Cernea, Valentin I ^a,c   Irimie, Alexandru ^a,c  

^a THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^b BABE BOLYAI UNIVERSITY   (Romania)

^c IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

cellular uptake; cisplatin; colorectal cancer cell line; cytotoxicity; DNA cross links; oxaliplatin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CELL DNA; CISPLATIN; OXALIPLATIN; PHENAZINE METHOSULFATE; SINPLATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG UPTAKE; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; COLORECTAL NEOPLASMS; DNA DAMAGE; DNA, NEOPLASM; HT29 CELLS; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 84867579034     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328355076f     Document Type: Article

References (24)

1. Wozniak K, Błasiak J. Recognition and repair of DNA-cisplatin adducts [review]. Acta Biochim Pol 2002; 49:583-596.
2. FoltinováV, SvihálkováSindlerováL, Horváth V, Sova P, Hofmanova J, Janisch R, Kozubik A. Mechanisms of effects of platinum (II) and (IV) complexes. Comparison of cisplatin and oxaliplatin with satraplatin and LA- 12, new Pt (IV)-based drugs. A Minireview. Scripta Medica (BRNO) 2008; 81:105-116.
3. Lévi F, Metzger G, Massari C, Milano G. Oxaliplatin: Pharmacokinetics and chronopharmacological aspects [review]. Clin Pharmacokinet 2000; 38: 1-21.
4. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52:1855-1865.
5. Holmes J, Stanko J, Varchenko M, Ding H, Madden VJ, Bagnell CR, et al. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 1998; 46:342-351.
6. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997; 8:876-885.
7. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin [review]. Mol Cancer Ther 2002; 1:227-235.
8. Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000; 58:920-927.
9. Moggs JG, Szymkowski DE, Yamada M, Karran P, Wood RD. Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts. Nucleic Acids Res 1997; 25:480-491.
10. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000; 35:206-221.
11. Virag P, Brie I, Fischer-Fodor E, Perde-Schrepler M, Tatomir C, Balacescu O, et al. Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance. Cell Biochem Funct 2011; 29:351-355.
12. Collins AR, Dobson VL, DusinskáM, Kennedy G, Stetina R. The comet assay: what it can really tell us? Mutat Res 1997; 375:183-193.
13. Sadowitz PD, Hubbard BA, Dabrowiak JC, Goodisman J, Tacka KA, Aktas MK, et al. Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. Drug Metab Dispos 2002; 30: 183-190.
14. Dunn TA, Schmoll HJ, Grunwald V, Grunwald V, Bokemeyer C, Casper J. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 1997; 15:109-114.
15. Ortuzar W, Paull K, Rixe O, Fojo T. Comparison of the activity of cisplatin (CP) and oxaliplatin (OXALI) alone or in combination in parental and drug resistant sublines [abstract]. Proc AACR 1994; 35:332.
16. Fukada M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 1995; 15:393-398.
17. Almeida GM, Duarte TL, Steward WP, Jones GDD. Detection of oxaliplatininduced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. DNA Repair 2006; 5:219-225.
18. Tippayamontri T, Kotb R, Paquette B, Sanche L. Cellular uptake and cytoplasm/DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116. Invest New Drugs 2011; 29:1321-1327.
19. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs [review]. Nat Rev Drug Discov 2005; 4:307-320.
20. Yang Z, Faustino PJ, Andrews PA, Monastra R, Rasmussen AA, Ellison CD, Cullen KJ. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother Pharmacol 2000; 46:255-262.
21. Jennerwein MM, Eastman A, Khokhar A. Characterization of adducts produced in DNA by isomeric 1, 2-diaminocyclohexaneplatinum (II) complexes. Chem Biol Interact 1989; 70:39-49.
22. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998; 58:3579-3585.
23. Ferry KV, Fink D, Johnson SW, Nebel S, Hamilton TC, Howell SB. Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells. Biochem Pharmacol 1999; 57:861-867.
24. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, NehméA, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56:4881-4886.